Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsMEX:TXG 60 Median PS Value is MXN0.00 as of Jul. 18, 2026. GuruFocus rates MEX:TXG with a GF Score™ of 60/100 and a GF Value™ of MXN142.66. The stock has 8 warning signs investors should review. Among 262 Healthcare Providers & Services companies, 10x Genomics ranks worse than 381679.01% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. 10x Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN92.81. 10x Genomics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is MXN0.00.
As of today (2026-07-18), 10x Genomics's share price is MXN335.54. 10x Genomics's Median PS Value is MXN0.00. Therefore, 10x Genomics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for 10x Genomics's Median PS Value or its related term are showing as below:
MEX:TXG's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
10x Genomics (MEX:TXG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
10x Genomics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
335.54
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics Median PS Value Related Terms
10x Genomics Median PS Value Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TXG vs DOCS, WAY, PRVA: Median PS Value Comparison
For the Health Information Services subindustry, 10x Genomics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
10x Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN92.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (MEX:TXG) has a Median PS Value of MXN0.00 as of Jul. 18, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #999999 out of 262 companies in the Healthcare Providers & Services industry.
Is 10x Genomics' Median PS Value too high?
10x Genomics' current Median PS Value is MXN0.00. Based on the distribution chart, 10x Genomics ranks #999999 out of 262 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Median PS Value compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #999999 out of 262 companies for Median PS Value. This places 10x Genomics in the lower half of its industry. The industry median Median PS Value is 0.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.71, based on 262 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Median PS Value is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current Median PS Value of MXN0.00. The stock's GF Value™ is MXN142.66, compared to a current price of MXN335.54 — trading 135.2% above its estimated fair value. The current Median PS Value is MXN0.00. 10x Genomics' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current Median PS Value is MXN0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 135.2% above its estimated GF Value™ of MXN142.66.
Key valuation signals for MEX:TXG:
Median PS Value: MXN0.00
GF Value™: MXN142.66 vs. price of MXN335.54 (135.2% above fair value)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
60GF Score
Get the complete analysis for MEX:TXG
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
